Clinical Trials Logo

Adenocarcinoma clinical trials

View clinical trials related to Adenocarcinoma.

Filter by:

NCT ID: NCT03738228 Recruiting - Clinical trials for Cervical Adenocarcinoma

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Start date: October 26, 2018
Phase: Phase 1
Study type: Interventional

This phase I trial studies how well atezolizumab before and/or with standard of care chemoradiotherapy works in immune system activation in patients with stage IB2, II, IIIB, or IVA cervical cancer that has spread to the lymph nodes. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab before and/or with chemoradiotherapy may lower the chance of tumors growing or spreading.

NCT ID: NCT03735290 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

ILIAD
Start date: November 30, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

Patients in the Phase 1b part of the study will be treated with ilixadencel at an increasing dose and frequency, in combination with standard doses and schedules of checkpoint inhibitor (CPI) pembrolizumab. The Phase 1b study will determine the optimal dose and schedule of ilixadencel. Patients in the Phase 2 part of the study will be randomly assigned to receive either ilixadencel (at the dose determined in Phase 1b) combined with the CPI, or only the CPI.

NCT ID: NCT03734913 Not yet recruiting - Glioblastoma Clinical Trials

A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors

Start date: December 20, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1602 in participants with basal cell carcinoma, adenocarcinoma of esophagogastric junction, small cell lung cancer, neuroendocrine neoplasm and other advanced solid tumors.

NCT ID: NCT03728374 Not yet recruiting - Clinical trials for Non-Small-Cell Lung Cancer

Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

Anlotinib is a multi-target receptor tyrosine kinase inhibitor in domestic research and development. It can inhibit the angiogenesis related kinase, such as VEGFR, FGFR, PDGFR, and tumor cell proliferation related kinase -c-Kit kinase. In the phase Ⅲ study, patients who failed at least two kinds of systemic chemotherapy (third line or beyond) or drug intolerance were treated with anlotinib(12mg,po. qd. on day 1to14 of a 21-day cycle) or placebo, the anlotinib group PFS and OS were 5.37 months and 9.63 months, the placebo group PFS and OS were 1.4 months and 6.3 months. Subgroup analysis results suggest that elderly patients may get longer mPFS and mOS. Therefore, the investigators envisage an open, single-arm, single-center clinical trial using anlotinib in elderly patients with EGFR wild-type lung adenocarcinoma who refused chemotherapy, to find if anlotinib is a better option in NSCLC second-line therapy.

NCT ID: NCT03727880 Not yet recruiting - Clinical trials for Pancreatic Ductal Adenocarcinoma

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma

Start date: November 2018
Phase: Phase 2
Study type: Interventional

This study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug, focal adhesion kinase inhibitor (FAK), defactinib, in people with "high risk" resectable (surgically removable) pancreatic cancer. The purpose of this study is to evaluate if reprograming the tumor microenvironment by targeting FAK following chemotherapy can potentiate anti-programmed death-1 (PD-1) antibody.

NCT ID: NCT03724994 Recruiting - Pancreatic Cancer Clinical Trials

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

CHAMP
Start date: September 1, 2018
Phase:
Study type: Observational [Patient Registry]

The CHAMP (Chemotherapy, Host response And Molecular dynamics in Periampullary cancer) study is a prospective, single-arm observational study that started Sept 1 2018. Patients diagnosed with pancreatic or other periampullary adenocarcinoma undergoing adjuvant och palliative chemotherapy are invited to participate. The study will examine the tumors' molecular dynamics and how this may change over time and with treatment. Primary endpoint will be overall survival, secondary endpoints will be disease specific survival, time to progression, and quality of life. We estimate that 90 patients will be included in the study per year.

NCT ID: NCT03724851 Not yet recruiting - Gastric Cancer Clinical Trials

Vactosertib in Combination With Pembrolizumab in Metastatic Colorectal or Gastric Cancer

Start date: November 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of vactosertib in combination with pembrolizumab in patients with metastatic or locally advanced colorectal or gastric/gastroesophageal junction adenocarcinoma

NCT ID: NCT03723915 Not yet recruiting - Clinical trials for Pancreatic Adenocarcinoma

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Start date: November 30, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well pembrolizumab in combination with pelareorep work in treating patients with pancreatic cancer that has spread to other parts of the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. A virus, called reovirus (pelareorep), which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. Giving pembrolizumab in combination with pelareorep may work better in treating patients with advanced pancreatic cancer.

NCT ID: NCT03722108 Not yet recruiting - Clinical trials for Adenocarcinoma of the Gastroesophageal Junction

Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas

REGIRI
Start date: January 2019
Phase: Phase 1/Phase 2
Study type: Interventional

Trial evaluating the efficacy of regorafenib combined with irinotecan compared to irinotecan alone in second-line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.

NCT ID: NCT03718338 Not yet recruiting - Clinical trials for Prostate Adenocarcinoma

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Prostate Adenocarcinoma

Start date: November 25, 2018
Phase: N/A
Study type: Interventional

This trial studies the mechanisms of metabolic and hormone action on plaque formation in brain and carotid vessels in participants with prostate adenocarcinoma. Studying the biomarkers in the laboratory may help doctors know the impact of androgen deprivation on metabolic, brain and cardiovascular endpoints.